MedTrace Logo

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

NCT06379113 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2025-08-11

No results posted yet for this study

Summary

To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.

Conditions

  • Endometrial Neoplasms
  • Atypical Endometrial Hyperplasia
  • Progesterone Resistance
  • Obesity

Interventions

DRUG

GnRH antagonist

Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.

DRUG

Letrozole 2.5mg

2.5mg po qd.

Sponsors & Collaborators

  • Xiaojun Chen

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-13
Primary Completion
2026-03-30
Completion
2027-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06379113 on ClinicalTrials.gov